<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GILOTRIF- afatinibÂ tablet, film coatedÂ </strong><br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information
needed to use GILOTRIF safely and effectively.  See full prescribing
information for GILOTRIF.<br>GILOTRIF<span class="Sup">Â®</span> (afatinib) tablets, for oral use<br>Initial U.S. Approval:
2013<br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<br><p class="Highlighta">GILOTRIF is a kinase inhibitor indicated for
the first-line treatment of patients with metastatic non-small cell
lung cancer (NSCLC) whose tumors have epidermal growth factor receptor
(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
as detected by an FDA-approved test (<a href="#Section_1">1</a>) </p>
<br><p class="Highlighta">Limitation of Use: Safety and efficacy of GILOTRIF
have not been established in patients whose tumors have other EGFR
mutations (<a href="#Section_1">1</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Recommended dose: 40 mg orally, once daily (<a href="#Section_2.2">2.2</a>)</li>
<li>Instruct patients to take GILOTRIF at least 1 hour before
or 2 hours after a meal (<a href="#Section_2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Tablets:  40 mg, 30 mg, and 20 mg (<a href="#Section_3">3</a>) </p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#Section_4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may result in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.
 Withhold GILOTRIF for severe and prolonged <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> not responsive
to anti-diarrheal agents. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.1">5.1</a>)</li>
<li>Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span>: Severe bullous,
<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, and exfoliating lesions occurred in 0.15% of patients.
 Discontinue for life-threatening cutaneous reactions.  Withhold GILOTRIF
for severe and prolonged cutaneous reactions. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> (ILD): Occurs in 1.5% of patients.
 Withhold GILOTRIF for acute onset or worsening of pulmonary symptoms.
Discontinue GILOTRIF if ILD is diagnosed. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.3">5.3</a>)</li>
<li>Hepatic toxicity:  Fatal <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> occurs in 0.18%
of patients. Monitor with periodic liver testing. Withhold or discontinue
GILOTRIF for severe or worsening liver tests. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>: Occurs in 0.8% of patients.  Withhold GILOTRIF
for <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> evaluation. Withhold or discontinue GILOTRIF for confirmed
<span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>. (<a href="#Section_2.3">2.3</a>, <a href="#Section_5.5">5.5</a>)</li>
<li>Embryofetal toxicity: Can cause fetal harm. Advise females
of the potential hazard to the fetus and to use highly effective contraception.
(<a href="#Section_5.6">5.6</a>)</li>
</ul>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥20%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>,
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">dermatitis acneiform</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, decreased
appetite, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (<a href="#Section_6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257
or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or <a href="#http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
<br>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Co-administration of P-gp inhibitors can increase
afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated.
Co-administration of chronic P-gp inducers orally can decrease afatinib
exposure. Increase GILOTRIF by 10 mg per day as tolerated. (<a href="#Section_2.3">2.3</a>, <a href="#Section_7">7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc"><li>Nursing mothers: Discontinue drug or nursing (<a href="#Section_8.3">8.3</a>)</li></ul>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1â€ƒâ€ƒINDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Patient Selection</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dose</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Modification</a></h2>
<h1><a href="#section-3" class="toc">3â€ƒâ€ƒDOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4â€ƒâ€ƒCONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Bullous and Exfoliative
<span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Interstitial Lung
Disease (ILD)</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatic Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Embryofetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6â€ƒâ€ƒADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7â€ƒâ€ƒDRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Females and Males
of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10â€ƒâ€ƒOVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11â€ƒâ€ƒDESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12â€ƒâ€ƒCLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14â€ƒâ€ƒCLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16â€ƒâ€ƒHOW SUPPLIED/STORAGE
AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1â€ƒâ€ƒINDICATIONS AND USAGE</h1>
<p class="First"><a name="P5"></a>GILOTRIF is indicated for the first-line treatment
of patients with metastatic non-small cell lung cancer (NSCLC) whose
tumors have epidermal growth factor receptor (EGFR) exon 19 deletions
or exon 21 (L858R) substitution mutations as detected by an FDA-approved
test <span class="Italics">[see Clinical Studies (<a href="#Section_14">14</a>)].</span></p>
<p><a name="p23351122"></a>Limitation of Use:
Safety and efficacy of GILOTRIF have not been established in patients
whose tumors have other EGFR mutations <span class="Italics">[see Clinical Studies
(<a href="#Section_14">14</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Patient Selection</h2>
<p class="First"><a name="p2336822"></a>Select patients for the first-line treatment
of metastatic NSCLC with GILOTRIF based on the presence of EGFR exon
19 deletions or exon 21 (L858R) substitution mutations in tumor specimens <span class="Italics">[see Indications and Usage (<a href="#Section_1">1</a>) and
Clinical Studies (<a href="#Section_14">14</a>)].</span> Information
on FDA-approved tests for the detection of EGFR mutations in NSCLC
is available at: http://www.fda.gov/CompanionDiagnostics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dose</h2>
<p class="First"><a name="p2564722"></a>The recommended dose of GILOTRIF is 40 mg
orally once daily until disease progression or no longer tolerated
by the patient. Take GILOTRIF at least 1 hour before or 2 hours after
a meal.</p>
<p><a name="p2566322"></a>Do not take a missed dose
within 12 hours of the next dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Modification</h2>
<p class="First"><a name="p2574322"></a>Withhold GILOTRIF for any drug-related adverse
reactions of:</p>
<ul class="Disc">
<li>NCI CTCAE* Grade 3 or higher</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> of Grade 2 or higher persisting for 2 or more consecutive
days while taking anti-diarrheal medication <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.1">5.1</a>)]</span>
</li>
<li>Cutaneous reactions of Grade 2 that are prolonged (lasting
more than 7 days) or intolerable <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.2">5.2</a>)]</span>
</li>
<li>Renal dysfunction of Grade 2 or higher</li>
</ul>
<p><a name="p18696622"></a>*National Cancer Institute Common
Terminology Criteria for Adverse Events, v 3.0</p>
<p><a name="p2858222"></a>Resume treatment when the adverse reaction fully resolves,
returns to baseline, or improves to Grade 1.  Reinstitute GILOTRIF
at a reduced dose, i.e., 10 mg per day less than the dose at which
the adverse reaction occurred.</p>
<p><a name="p2861222"></a>Permanently discontinue GILOTRIF for:</p>
<ul class="Disc">
<li>Life-threatening bullous, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, or exfoliative skin
lesions <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>)]</span>
</li>
<li>Confirmed <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (ILD) <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.3">5.3</a>)]</span>
</li>
<li>Severe drug-induced <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.4">5.4</a>)]</span>
</li>
<li>Persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span> <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.5">5.5</a>)]</span>
</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span></li>
<li>Severe or intolerable adverse reaction occurring at a dose
of 20 mg per day</li>
</ul>
<p><a name="p3610622"></a><span class="Italics">P-gp Inhibitors</span><br>For patients who require therapy with a P-glycoprotein (P-gp) inhibitor,
reduce GILOTRIF daily dose by 10 mg if not tolerated. Resume the previous
dose after discontinuation of the P-gp inhibitor as tolerated <span class="Italics">[see Drug Interactions (<a href="#Section_7">7</a>) and Clinical
Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>.</p>
<p><a name="p3608422"></a><span class="Italics">P-gp Inducers</span><br>For patients who require chronic therapy with a P-gp inducer, increase
GILOTRIF daily dose by 10 mg as tolerated. Resume the previous dose
2 to 3 days after discontinuation of the P-gp inducer <span class="Italics">[see
Drug Interactions (<a href="#Section_7">7</a>) and Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3â€ƒâ€ƒDOSAGE FORMS AND
STRENGTHS</h1>
<p class="First"><a name="P7"></a>GILOTRIF is available
as:<br>40 mg tablets: light blue, film-coated, round, biconvex,
bevel-edged tablets debossed with â€œT40â€? on one side and the Boehringer
Ingelheim company symbol on the other side.</p>
<p><a name="p3620522"></a>30 mg tablets: dark blue, film-coated, round, biconvex,
bevel-edged tablets debossed with â€œT30â€? on one side and the Boehringer
Ingelheim company symbol on the other side.</p>
<p><a name="p3622322"></a>20 mg tablets: white to slightly yellowish, film-coated,
round, biconvex, bevel-edged tablets debossed with â€œT20â€? on one side
and the Boehringer Ingelheim company symbol on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4â€ƒâ€ƒCONTRAINDICATIONS</h1>
<p class="First"><a name="P8"></a>None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><a name="p3624722"></a><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> has resulted in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> with
or without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; some of these cases were fatal. In Study
1, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 96% of patients treated with GILOTRIF (n=229),
of which 15% was Grade 3 in severity and occurred within the first
6 weeks <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> as a consequence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred
in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were
Grade 3.</p>
<p><a name="p3630322"></a>For patients who develop
prolonged Grade 2 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> lasting more than 48 hours or greater than
or equal to Grade 3 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, withhold GILOTRIF until <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolves
to Grade 1 or less, and resume GILOTRIF with appropriate dose reduction <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)].</span>  Provide patients with an anti-diarrheal agent (e.g.,
loperamide) for self-administration at the onset of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and instruct
patients to continue anti-diarrheal therapy until <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose bowel</span> movements
cease for 12 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Bullous and Exfoliative
<span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></h2>
<p class="First"><a name="p3851322"></a>Grade
3 cutaneous reactions characterized by bullous, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, and exfoliating
lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF
across clinical trials <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span> In Study 1, the overall
incidence of cutaneous reactions consisting of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and
acneiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 90%, and the incidence of Grade 3 cutaneous reactions
was 16%.  In addition, the incidence of Grade 1-3 palmar-plantar erythrodysesthesia
syndrome was 7%.  Discontinue GILOTRIF in patients who develop life-threatening
bullous, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, or exfoliating lesions<span class="Italics"> [see Dosage and
Administration (<a href="#Section_2.3">2.3</a>)].</span>  For
patients who develop prolonged Grade 2 cutaneous adverse reactions
lasting more than 7 days, intolerable Grade 2, or Grade 3 cutaneous
reactions, withhold GILOTRIF until the adverse reaction resolves to
Grade 1 or less, and resume GILOTRIF with appropriate dose reduction <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Interstitial Lung
Disease (ILD)</h2>
<p class="First"><a name="p3871322"></a>ILD or
ILD-like adverse reactions (e.g., lung infiltration, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>,
<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, or <span class="product-label-link" type="condition" conceptid="433233" conceptname="Mushroom workers' lung">alveolitis allergic</span>) occurred
in 1.5% of the 3865 patients who received GILOTRIF across clinical
trials; of these, 0.4% were fatal. The incidence of ILD appeared to
be higher in patients of Asian ethnicity (2.1%) as compared to non-Asians
(1.2%).  In Study 1, the incidence of Grade â‰¥3 ILD was 1.3% and resulted
in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in 1% of GILOTRIF-treated patients.</p>
<p><a name="p3874322"></a>Withhold GILOTRIF during evaluation of patients with
suspected ILD, and discontinue GILOTRIF in patients with confirmed
ILD <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatic Toxicity</h2>
<p class="First"><a name="p3884322"></a>In 3865 patients who received GILOTRIF across
clinical trials, 10.1% had liver test abnormalities, of which 7 (0.18%)
were fatal.  In Study 1, liver test abnormalities of any grade occurred
in 17.5% of the patients treated with GILOTRIF.</p>
<p><a name="p4096122"></a>Obtain periodic liver testing in patients during treatment
with GILOTRIF. Withhold GILOTRIF in patients who develop worsening
of liver function <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>)]</span>. In patients who develop
severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> while taking GILOTRIF, treatment should
be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></h2>
<p class="First"><a name="p4111222"></a><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>, characterized as acute or worsening
<span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, light sensitivity, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>,
<span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, and/or <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eye</span> occurred in 0.8% of patients treated with
GILOTRIF among 3865 patients across clinical trials. <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> was
reported in 5 (2.2%) patients in Study 1, with Grade 3 in 1 (0.4%).
 Withhold GILOTRIF during evaluation of patients with suspected <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>,
and if diagnosis of <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span> is confirmed, treatment with
GILOTRIF should be interrupted or discontinued <span class="Italics">[see Dosage
and Administration (<a href="#Section_2.3">2.3</a>)]</span>. If <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> is diagnosed, the benefits and risks of continuing
treatment should be carefully considered. GILOTRIF should be used
with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">ulcerative keratitis</span>,
or severe <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span> <span class="Italics">[see Adverse Reactions (<a href="#Section_6.1">6.1</a>)]</span>. Contact lens use is also
a risk factor for <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and ulceration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Embryofetal Toxicity</h2>
<p class="First"><a name="p4143422"></a>Based on its mechanism of action, GILOTRIF
can cause fetal harm when administered to a pregnant woman. Afatinib
was embryotoxic and, in animals with maternal toxicity, led to abortions
at late gestational stages in rabbits at doses of 5 mg/kg (approximately
0.2 times the human exposure at the recommended dose of 40 mg daily)
or greater.  If this drug is used during pregnancy, or if the patient
becomes pregnant while taking this drug, the patient should be apprised
of the potential hazard to the fetus <span class="Italics">[see Use in Specific
Populations (<a href="#Section_8.1">8.1</a>)].</span></p>
<p><a name="p4352122"></a>Advise females of reproductive potential
to use highly effective contraception during treatment, and for at
least 2 weeks after the last dose of GILOTRIF. Advise patients to
contact their healthcare provider if they become pregnant, or if pregnancy
is suspected, while taking GILOTRIF <span class="Italics">[see Use in Specific Populations
(<a href="#Section_8.1">8.1</a> and <a href="#Section_8.6">8.6</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6â€ƒâ€ƒADVERSE REACTIONS</h1>
<p class="First"><a name="P10"></a>The
following adverse reactions are discussed in greater detail in other
sections of the labeling:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)]</span>
</li>
<li>Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span> <span class="Italics">[see Warnings
and Precautions (<a href="#Section_5.2">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.3">5.3</a>)]</span>
</li>
<li>Hepatic Toxicity <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.4">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><a name="p48751522"></a>Because clinical trials are conducted under
widely varying conditions, adverse reaction rates observed in the
clinical trials of a drug cannot be directly compared to rates in
the clinical trials of another drug and may not reflect the rates
observed in practice.</p>
<p><a name="p4878222"></a>The safety
evaluation of GILOTRIF is based on the data from more than 3800 patients,
including 2135 NSCLC patients receiving GILOTRIF monotherapy at or
above the recommended dose.</p>
<p><a name="p4880222"></a><span class="Italics">Controlled Study</span><br>The data in Tables 1 and 2 below
reflect exposure of 229 EGFR-TKI naÃ¯ve GILOTRIF-treated patients with
EGFR mutation-positive, metastatic, non-squamous, NSCLC enrolled in
a randomized, multicenter, open-label trial (Study 1). Patients received
GILOTRIF 40 mg daily until documented disease progression or intolerance
to the therapy. A total of 111 patients were treated with pemetrexed/cisplatin.
 Patients were treated with pemetrexed 500 mg/mÂ² followed after 30
minutes by cisplatin 75 mg/mÂ² every three weeks for a maximum of six
treatment courses.</p>
<p><a name="p4882222"></a>The median
exposure was 11.0 months for patients treated with GILOTRIF and 3.4
months for patients treated with pemetrexed/cisplatin.  The overall
trial population had a median age of 61 years; 61% of patients in
the GILOTRIF arm and 60% of patients in the pemetrexed/cisplatin arm
were younger than 65 years. A total of 64% of patients on GILOTRIF
and 67% of pemetrexed/cisplatin patients were female. More than two-thirds
of patients were from Asia (GILOTRIF 70%; pemetrexed/cisplatin 72%).</p>
<p><a name="p4884222"></a>Serious adverse reactions were reported
in 29% of patients treated with GILOTRIF. The most frequent serious
adverse reactions reported in patients treated with GILOTRIF were
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.6%); <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4.8%); and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>
(1.7% each). Fatal adverse reactions in GILOTRIF-treated patients
in Study 1 included pulmonary toxicity/ILD-like adverse reactions
(1.3%), <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> (0.43%), and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (0.43%).</p>
<p><a name="p4886222"></a>Dose reductions due to adverse reactions were required
in 57% of GILOTRIF-treated patients. The most frequent adverse reactions
that led to dose reduction in the patients treated with GILOTRIF were
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (20%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (19%), <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span> (14%), and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>
(10%).</p>
<p><a name="p4888222"></a>Discontinuation of therapy
in GILOTRIF-treated patients for adverse reactions was 14.0%. The
most frequent adverse reactions that led to discontinuation in GILOTRIF-treated
patients were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1.3%), ILD (0.9%), and <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span> (0.9%).</p>
<p><a name="p2350422"></a>Clinical trials of GILOTRIF excluded patients
with an abnormal left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF), i.e.,
below the institutional lower limit of normal. In Study 1, all patients
were evaluated for LVEF at screening and every 9 weeks thereafter
in the GILOTRIF-treated group and as needed in the pemetrexed/cisplatin
group. More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular
dysfunction (defined as <span class="product-label-link" type="condition" conceptid="141038" conceptname="Diastolic dysfunction">diastolic dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>,
or ventricular dilation; all &lt; Grade 3) compared to chemotherapy-treated
patients (0.9%; n=1).</p>
<a name="t48891122"></a><table border="0" width="100%">
<caption><span>Table 1 Adverse Reactions Reported in â‰¥10% of GILOTRIF-Treated
Patients in Study 1</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">*None of the adverse reactions in this table except
<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (one patient on GILOTRIF [0.4%]) were Grade 4 in severity<br><span class="Sup">1</span>Includes <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>,
<span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="4122123" conceptname="Erosion of oral mucosa">oral mucosa erosion</span>, mucosal
erosion, <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">mucosal ulceration</span><br><span class="Sup">2</span>Includes group of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> preferred terms, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4243513" conceptname="Pustular acne">acne pustular</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>
acneiform<br><span class="Sup">3</span>Includes <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span>,
<span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span>, <span class="product-label-link" type="condition" conceptid="4316194" conceptname="Nail bed infection">nail bed infection</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â </td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">GILOTRIF<br>n=229</span></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Pemetrexed/Cisplatin<br>n=111</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">All Grades<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Grade 3*<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">All Grades<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Grade 3*<br>(%)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Gastrointestinal
disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule Rrule Toprule">96</td>
<td class="Botrule Lrule Rrule Toprule">15</td>
<td class="Botrule Lrule Rrule Toprule">23</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule">71</td>
<td class="Botrule Lrule Rrule Toprule">9</td>
<td class="Botrule Lrule Rrule Toprule">15</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule">25</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
<td class="Botrule Lrule Rrule Toprule">68</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule">23</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
<td class="Botrule Lrule Rrule Toprule">47</td>
<td class="Botrule Lrule Rrule Toprule">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span></td>
<td class="Botrule Lrule Rrule Toprule">12</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Skin and subcutaneous
tissue disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>/<span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Dermatitis acneiform</span><span class="Sup">2</span>
</td>
<td class="Botrule Lrule Rrule Toprule">90</td>
<td class="Botrule Lrule Rrule Toprule">16</td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Lrule Rrule Toprule">21</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Lrule Rrule Toprule">31</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>
and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">Paronychia</span><span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule">58</td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span></td>
<td class="Botrule Lrule Rrule Toprule">13</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
<td class="Botrule Lrule Rrule Toprule">5</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Metabolism
and nutrition disorders</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Lrule Rrule Toprule">29</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
<td class="Botrule Lrule Rrule Toprule">55</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Respiratory,
thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td class="Botrule Lrule Rrule Toprule">17</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">6</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Investigations</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span></td>
<td class="Botrule Lrule Rrule Toprule">17</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
<td class="Botrule Lrule Rrule Toprule">14</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">General disorders
and administration site conditions</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Botrule Lrule Rrule Toprule">12</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">6</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
<td class="Botrule Lrule Rrule Toprule">3</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
</tbody>
</table>
<a name="t43921522"></a><table border="0" width="70%">
<caption><span>Table 2  Adverse Reactions of Laboratory Abnormalities from
the Investigations SOC Reported in â‰¥5% of GILOTRIF-Treated Patients
in Study 1</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1</span>Includes <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>,
<span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> decreased<br>SOC=system organ class</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â </td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">GILOTRIF<br>n=229</span></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Pemetrexed/Cisplatin<br>n=111</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">All Grades<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Grades 3-4<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">All Grades<br>(%)</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Grades 3-4<br>(%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
<td class="Botrule Lrule Rrule Toprule">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span><span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule">11</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
<td class="Botrule Lrule Rrule Toprule">5</td>
<td class="Botrule Lrule Rrule Toprule">4</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td class="Botrule Lrule Rrule Toprule">8</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
<td class="Botrule Lrule Rrule Toprule">2</td>
<td class="Botrule Lrule Rrule Toprule">1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s210111301437106278"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First"><a name="p1565212301437106314"></a>The following adverse reactions have been
identified during post-approval use of GILOTRIF. Because these reactions
are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or establish
a causal relationship to drug exposure.</p>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></li></ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7â€ƒâ€ƒDRUG INTERACTIONS</h1>
<p class="First"><a name="P11"></a><span class="Italics">Effect of P-glycoprotein (P-gp) Inhibitors
and Inducers</span><br>Oral administration of a P-gp inhibitor
(ritonavir at 200 mg twice daily) 1 hour before administration of
GILOTRIF increased systemic exposure to afatinib by 48%.  There was
no change in afatinib exposure when ritonavir was administered simultaneously
with or 6 hours after GILOTRIF. Concomitant taking of P-gp inhibitors
(including but not limited to ritonavir, cyclosporine A, ketoconazole,
itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir,
saquinavir, and amiodarone) with GILOTRIF can increase exposure to
afatinib <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
<p><a name="p7691322"></a>Co-administration with oral dose of a P-gp inducer (rifampicin
at 600 mg once daily for 7 days) decreased exposure to afatinib by
34%. Concomitant taking of P-gp inducers (including but not limited
to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johnâ€™s
Wort) with GILOTRIF can decrease exposure to afatinib <span class="Italics">[see
Dosage and Administration (<a href="#Section_2.3">2.3</a>) and
Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><a name="P13"></a>Pregnancy Category
D</p>
<p><a name="p7692322"></a><span class="Italics">Risk Summary</span><br>Based on its mechanism of action, GILOTRIF can cause
fetal harm when administered to a pregnant woman. Afatinib was embryotoxic
and, in animals with maternal toxicity, led to abortions at late gestational
stages in rabbits at doses of 5 mg/kg (approximately 0.2 times the
exposure by AUC at the recommended human dose of 40 mg daily) or greater.
If this drug is used during pregnancy, or if the patient becomes pregnant
while taking this drug, the patient should be apprised of the potential
hazard to the fetus <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.6">5.6</a>)].</span></p>
<p><a name="p7699122"></a><span class="Italics">Animal Data</span><br>Administration
of afatinib to pregnant rabbits at doses of 5 mg/kg (approximately
0.2 times the exposure by AUC at the recommended human dose of 40
mg daily) or greater during the period of organogenesis caused increased
post implantation loss and, in animals showing maternal toxicity,
abortion at late gestational stages.  In the same study, at the high
dose level of 10 mg/kg (approximately 0.7 times the exposure by AUC
at the recommended human dose of 40 mg daily) there were reduced fetal
weights, and increases in the incidence of runts, as well as visceral
and dermal variations.  In an embryofetal development study in rats,
there were skeletal alterations consisting of incomplete or delayed
ossifications and reduced fetal weight at a dose of 16 mg/kg (approximately
twice the exposure at the recommended human dose of 40 mg daily).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="p7729322"></a>It is not known whether afatinib is present in human milk.  Afatinib
was present in the milk of lactating rats at concentrations 80-150
times higher than those found in plasma from 1 to 6 hours after administration.
Because many drugs are present in human milk and because of the potential
for serious adverse reactions in nursing infants from GILOTRIF, a
decision should be made whether to discontinue nursing or to discontinue
the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="P18"></a>Safety
and effectiveness of GILOTRIF in pediatric patients have not been
established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="P19"></a>Of the
3865 patients in the clinical studies of GILOTRIF, 32% of patients
were 65 years and older, while 7% were 75 years and older. No overall
differences in safety were observed between patients 65 years and
over and younger patients. In Study 1, 39% of the 345 patients were
65 years of age or older and 4% were 75 years or older. No overall
differences in effectiveness were observed between patients 65 years
and older and younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Females and Males
of Reproductive Potential</h2>
<p class="First"><a name="p7721322"></a><span class="Italics">Contraception</span><br><span class="Underline">Females</span><br>Counsel patients on pregnancy planning and prevention.
 Advise female patients of reproductive potential to use highly effective
contraception during treatment with GILOTRIF, and for at least 2 weeks
after the last dose of GILOTRIF.  Advise patients to contact their
healthcare provider if they become pregnant, or if pregnancy is suspected,
while taking GILOTRIF <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.1">8.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"><a name="p796422"></a>GILOTRIF has not been studied in patients
with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance [CLcr]
&lt;30 mL/min).  Adjustments to the starting dose of GILOTRIF are
not considered necessary in patients with mild (CLcr 60-89 mL/min)
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Closely monitor patients with moderate (CLcr 30-59
mL/min) to severe (CLcr &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and adjust
GILOTRIF dose if not tolerated <span class="Italics">[see Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="p7943322"></a>GILOTRIF has not been studied in patients
with severe (Child Pugh C) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  Adjustments to the
starting dose of GILOTRIF are not considered necessary in patients
with mild (Child Pugh A) or moderate (Child Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
Closely monitor patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and adjust
GILOTRIF dose if not tolerated <span class="Italics">[see Clinical Pharmacology
(<a href="#Section_12.3">12.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10â€ƒâ€ƒOVERDOSAGE</h1>
<p class="First"><a name="P24"></a><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> was
reported in 2 healthy adolescents each of whom ingested 360 mg of
GILOTRIF (as part of a mixed-drug ingestion) resulting in <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and elevated
amylase (&lt;1.5 times upper limit of normal [ULN]). Both subjects
recovered.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11â€ƒâ€ƒDESCRIPTION</h1>
<p class="First"><a name="P25"></a>GILOTRIF tablets contain afatinib, a tyrosine
kinase inhibitor which is a 4-anilinoquinazoline. Afatinib is presented
as the dimaleate salt, with the chemical name 2-butenamide, <span class="Italics">N</span>-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3<span class="Italics">S</span>)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2<span class="Italics">E</span>)-, (2<span class="Italics">Z</span>)-2-butenedioate (1:2).  Its structural
formula is:</p>
<div class="Figure"><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=gilotrif-struct.jpg"></div>
<p><a name="p1042322"></a>Afatinib dimaleate is a white to brownish yellow powder, water soluble
and hygroscopic, with an empirical formula of C<span class="Sub">32</span>H<span class="Sub">33</span>ClFN<span class="Sub">5</span>O<span class="Sub">11</span>, and a molecular weight of 718.1 g/mol.</p>
<p><a name="p1040322"></a>GILOTRIF tablets for oral administration
are available in 40 mg, 30 mg, or 20 mg of afatinib (equivalent to
59.12 mg, 44.34 mg, or 29.56 mg afatinib dimaleate, respectively).
 The inactive ingredients of GILOTRIF are the following: Tablet Core:
 lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal
silicon dioxide, magnesium stearate.  Coating: hypromellose, polyethylene
glycol, titanium dioxide, talc, polysorbate 80, FD&amp;C Blue No.
2 (40 mg and 30 mg tablets only).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12â€ƒâ€ƒCLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="P27"></a>Afatinib covalently binds to the kinase domains of EGFR (ErbB1),
HER2 (ErbB2), and HER4 (ErbB4) and irreversibly inhibits tyrosine
kinase autophosphorylation, resulting in downregulation of ErbB signaling.</p>
<p><a name="p1289422"></a>Afatinib demonstrated inhibition of autophosphorylation
and <span class="Italics">in vitro</span> proliferation of cell lines expressing
wild-type EGFR or those expressing selected EGFR exon 19 deletion
mutations or exon 21 L858R mutations, including some with a secondary
T790M mutation, at afatinib concentrations achieved, at least transiently,
in patients.  In addition, afatinib inhibited <span class="Italics">in vitro</span> proliferation of cell lines overexpressing HER2.</p>
<p><a name="p7947522"></a>Treatment with afatinib resulted in inhibition of tumor
growth in nude mice implanted with tumors either overexpressing wild
type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><a name="p14374722"></a><span class="Italics">Cardiac Electrophysiology</span><br>The effect
of multiple doses of GILOTRIF (50 mg once daily) on the QTc interval
was evaluated in an open-label, single-arm study in patients with
relapsed or refractory <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.  No large changes in the mean
QTc interval (i.e., &gt;20 ms) were detected in the study.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="P28"></a><span class="Italics">Absorption and Distribution</span><br>Following oral administration
of GILOTRIF tablets, time to peak afatinib plasma concentrations (T<span class="Sub">max</span>) is 2 to 5 hours.  Maximum concentration (C<span class="Sub">max</span>) and area under the concentration-time curve from
time zero to infinity (AUC<span class="Sub">0-âˆž</span>) values increased
slightly more than dose proportional in the range of 20Â to 50 mg.
The geometric mean relative bioavailability of 20 mg GILOTRIF tablets
was 92% as compared to an oral solution. <span class="Italics">In vitro</span> binding of afatinib to human plasma proteins is approximately 95%.</p>
<p><a name="p7946822"></a>A high-fat meal decreased C<span class="Sub">max</span> by 50% and AUC<span class="Sub">0-âˆž</span> by 39% relative to the
fasted condition <span class="Italics">[see Dosage and Administration (<a href="#Section_2.2">2.2</a>)]</span>.</p>
<p><a name="p7985222"></a><span class="Italics">Metabolism and Elimination</span><br>Covalent adducts to proteins are the major circulating metabolites
of afatinib and enzymatic metabolism of afatinib is minimal.</p>
<p><a name="p8193122"></a>In humans, excretion of afatinib is primarily <span class="Italics">via</span> the feces (85%) with 4% recovered in the urine following
a single oral dose of [<span class="Sup">14</span>C]-labeled afatinib
solution.  The parent compound accounted for 88% of the recovered
dose.</p>
<p><a name="p8195122"></a>The elimination half-life
of afatinib is 37 hours after repeat dosing in cancer patients.  Steady-state
plasma concentrations are achieved within 8 days of repeat dosing
of GILOTRIF resulting in an accumulation of 2.8-fold for AUC and 2.1-fold
for C<span class="Sub">max</span>.</p>
<p><a name="p8197122"></a><span class="Italics">Specific Populations</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span>  The median trough afatinib plasma concentrations in patients with
mild (CLcr 60-89 mL/min) and moderate (CLcr 30-59 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
were 27% and 85% higher than those in patients with normal renal function
(CLcr â‰¥90 mL/min).  GILOTRIF has not been studied in patients with
severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (CLcr &lt;30 mL/min) <span class="Italics">[see
Use in Specific Populations (<a href="#Section_8.7">8.7</a>)]</span>.</p>
<p><a name="p8199122"></a><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span>  Afatinib is eliminated mainly by biliary/fecal excretion. Mild
(Child Pugh A) or moderate (Child Pugh B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> had no
influence on the afatinib exposure following a single dose of GILOTRIF.
 Subjects with severe (Child Pugh C) hepatic dysfunction have not
been studied <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.8">8.8</a>)]</span>.</p>
<p><a name="p8201122"></a><span class="Italics">Body Weight, Gender, Age, and Race:</span>  Based on the population pharmacokinetic analysis, weight, gender,
age, and race do not have a clinically important effect on exposure
of afatinib.</p>
<p><a name="p8203122"></a><span class="Italics">Drug Interactions</span><br><span class="Italics">Effect of P-gp Inhibitors and Inducers on Afatinib:</span> The effect of ritonavir dosing time relative to a single oral dose
of GILOTRIF was evaluated in healthy subjects taking 40 mg of GILOTRIF
alone as compared to those after ritonavir (200 mg twice daily for
3 days) co-administration at 6 hours after GILOTRIF administration.
 The relative bioavailability for AUC<span class="Sub">0-âˆž</span> and
C<span class="Sub">max</span> of afatinib was 119% and 104% when co-administered
with ritonavir, and 111% and 105% when ritonavir was administered
6 hours after taking GILOTRIF.  In another study, when ritonavir (200
mg twice daily for 3 days) was administered 1 hour before a 20 mg
single dose of GILOTRIF, exposure to afatinib increased by 48% for
AUC<span class="Sub">0-âˆž</span> and 39% for C<span class="Sub">max</span><span class="Italics"> [see Drug Interactions (<a href="#Section_7">7</a>)].</span></p>
<p><a name="p8456422"></a>Pre-treatment with a potent
inducer of P-gp, rifampicin (600 mg once daily for 7 days) decreased
the plasma exposure to afatinib by 34% (AUC<span class="Sub">0-âˆž</span>) and 22% (C<span class="Sub">max</span>) <span class="Italics">[see Drug Interactions
(<a href="#Section_7">7</a>)]</span>.</p>
<p><a name="p8469222"></a><span class="Italics">P-glycoprotein (P-gp): </span>Based on <span class="Italics">in vitro </span>data, afatinib is a substrate and an inhibitor
of P-gp.</p>
<p><a name="p8471222"></a><span class="Italics">Breast Cancer
Resistance Protein (BCRP):</span>  Based on <span class="Italics">in vitro</span> data, afatinib is a substrate and an inhibitor of the transporter
BCRP.</p>
<p><a name="p8473222"></a><span class="Italics">Effect of CYP450
Enzyme Inducers and Inhibitors on Afatinib: In vitro</span> data
indicated that drug-drug interactions with GILOTRIF due to inhibition
or induction of CYP450 enzymes by concomitant medications are unlikely.
The metabolites formed by CYP450-dependent reactions were approximately
9% of the total metabolic turnover in sandwich-cultured human hepatocytes.
In humans, enzyme-catalyzed metabolic reactions play a negligible
role for the metabolism of afatinib. Approximately 2% of the afatinib
dose was metabolized by FMO3; the CYP3A4-dependent N-demethylation
was not detected.</p>
<p><a name="p8475222"></a><span class="Italics">Effect
of Afatinib on CYP450 Enzymes: </span>Afatinib is not an inhibitor
or an inducer of CYP450 enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, and
3A4) in cultured primary human hepatocytes.  Therefore, afatinib is
unlikely to affect the metabolism of other drugs that are substrates
of CYP450 enzymes.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="P30"></a>Carcinogenicity studies have not been conducted
with afatinib.</p>
<p><a name="p1321422"></a>A marginal response
to afatinib was observed in a single tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of a bacterial
(Ames) mutagenicity assay.  No mutagenic or genotoxic potential was
identified in an <span class="Italics">inÂ vitro</span> chromosomal aberration
test at non-cytotoxic concentrations as well as in the <span class="Italics">inÂ vivo</span> bone marrow micronucleus assay, the <span class="Italics">in vivo</span> Comet
assay, and an <span class="Italics">in vivo </span>4-week oral mutation study
in the Muta<span class="Sup">â„¢</span> Mouse.</p>
<p><a name="p8960222"></a>In a dedicated fertility study, male and female rats
received afatinib daily by oral administration at doses of 4, 6, or
8 mg/kg.  In males at doses of 6 mg/kg (approximately equal to the
exposure by AUC in patients at the recommended human dose of 40 mg
daily) or greater, there was an increase in the incidence of low or
no sperm count, though overall fertility was not affected; decreases
in sperm count were supported by findings of increased <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> in
the testes and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> in the seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> and the prostate in
general toxicology studies.  In females at the high dose of 8 mg/kg
(approximately 0.63 times the exposure by AUC in patients at the recommended
human dose of 40 mg daily), there was a mild decrease in the number
of corpora lutea along with a mild increase in post-implantation loss
due to early resorptions.  In a 4-week general toxicology study, female
rats had decreases in ovarian weights at all dose levels; organ weight
had not fully recovered by the end of a 2-week recovery period.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14â€ƒâ€ƒCLINICAL STUDIES</h1>
<p class="First"><a name="P32"></a><span class="Bold">Non-small Cell Lung Cancer (NSCLC)</span></p>
<p><a name="p1542322"></a><span class="Italics">Study 1</span><br>The efficacy and
safety of GILOTRIF in the first-line treatment of 345 patients with
EGFR mutation-positive, metastatic (Stage IV and Stage IIIb with pleural
and/or <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span> as classified by the American Joint Commission
on Cancer [AJCC, 6th edition]) NSCLC were established in a randomized,
multicenter, open-label trial (Study 1). Patients were randomized
(2:1) to receive GILOTRIF 40 mg orally once daily (n=230) or up to
6 cycles of pemetrexed/cisplatin (n=115). Randomization was stratified
according to EGFR mutation status (exon 19 deletion vs exon 21 L858R
vs other) and race (Asian vs non-Asian). The major efficacy outcome
was progression-free survival (PFS) as assessed by an independent
review committee (IRC). Other efficacy outcomes included objective
response rate (ORR) and overall survival (OS). EGFR mutation status
was prospectively determined for screening and enrollment of patients
by a clinical trial assay (CTA).  Tumor samples from 264 patients
(178 randomized to GILOTRIF and 86 patients randomized to chemotherapy)
were tested retrospectively by the companion diagnostic <span class="Italics">therascreen</span><span class="Sup">Â®</span> EGFR RGQ PCR Kit, which is FDA-approved
for selection of patients for GILOTRIF treatment.</p>
<p><a name="p8989422"></a>Among the patients randomized, 65% were female, the
median age was 61 years, the baseline ECOG performance status was
0 (39%) or 1 (61%), 26% were Caucasian and 72% were Asian. The majority
of the patients had a tumor sample with an EGFR mutation categorized
by the CTA as either exon 19 deletion (49%) or exon 21 L858R substitution
(40%), while the remaining 11% had other mutations.</p>
<p><a name="p8990322"></a>A statistically significant improvement in PFS as determined
by the IRC was demonstrated for patients randomized to GILOTRIF compared
with those randomized to chemotherapy.  See Table 3 and Figure 1.
There was no statistically significant difference for overall survival
between the treatment arms at the interim analysis conducted at 84%
of the planned events for the final analysis.</p>
<a name="t8994322"></a><table border="0" width="90%">
<caption><span>Table 3: Efficacy Results of Study 1</span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<tfoot><tr class="First Last"><td colspan="3">*Stratified by EGFR mutation status and race.<br>CR=complete response; PR=partial response</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">GILOTRIF<br>(N=230)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Pemetrexed/Cisplatin<br>(N=115)</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">Progression-free
Survival</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> or Progressions,
N (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">152 (66.1%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">69 (60.0%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†Median Progression-free
Survival (months)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.9</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†95% CI</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(9.6, 13.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(5.4, 8.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†HR (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">0.58
(0.43, 0.78)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†Stratified Log-Rank
Test P-value*</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">&lt;0.001</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">Overall Survival</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span>, N (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">116 (50.4%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">59 (51.2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†Median Overall Survival
(months)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28.1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†95% CI</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(24.6, 33.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">(20.7, 33.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†HR (95% CI)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">0.91
(0.66, 1.25)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†Stratified Log-Rank
Test P-value*</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">0.55</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">Objective
Response Rate (CR + PR)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">N (%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">116 (50.4%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">22 (19.1%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">Response Duration</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">Median (months)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.7</td>
</tr>
</tbody>
</table>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=gilotrif-fig1.jpg"></div>
<p><a name="p9738322"></a>Subgroup analyses were conducted based on the stratification factor
of EGFR mutation status (Del19, L858R, other) and mutation category
(common [Del19, L858R] vs uncommon [other]).  See Figure 2.</p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=gilotrif-fig2.jpg"></div>
<p><a name="p9769322"></a>There were 26 GILOTRIF-treated patients in the â€œotherâ€? (uncommon)
EGFR mutations subgroup with nine unique mutation patterns. None of
these 26 patients achieved a complete response, while four achieved
a partial response (see Table 4 below). No responses were seen in
GILOTRIF-treated patients with the following mutations: T790M alone
(n=2), deletion 19 and T790M (n=3), G719X and T790M (n=1), exon 20
insertion (n=6), and L861Q alone (n=3).  There were 11 chemotherapy-treated
patients in the â€œotherâ€? uncommon EGFR mutation subgroup; of these,
four (36%) achieved a partial response.</p>
<a name="t9767422"></a><table border="0" width="90%">
<caption><span>Table 4 Objective Tumor Responses in GILOTRIF-Treated Patients
Based on Investigator Assessment in the â€œOtherâ€? (Uncommon) EGFR Mutation
Subgroup</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
</colgroup>
<tfoot><tr class="First Last"><td colspan="4">+ Censored observation</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">EGFR Mutations</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Number of GILOTRIF-Treated
Patients</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Number of Patients with
Partial Responses</span></td>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Duration of Response</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†L858R and T790M</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â€†â€† 6.9 months</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†L858R and S768I</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12.4+ months</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†S768I</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16.5+ months</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule">â€†â€†â€†â€†â€†â€†â€†â€†G719X</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">â€†â€† 9.6 months</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16â€ƒâ€ƒHOW SUPPLIED/STORAGE
AND HANDLING</h1>
<p class="First"><a name="P34"></a>GILOTRIF tablets
are available as follows:<br>40 mg:  light blue, film-coated,
round, biconvex, bevel-edged tablets debossed with â€œT40â€? on one side
and the Boehringer Ingelheim company symbol on the other side.<br>Unit of use bottles of 30â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†NDC:  0597-0138-30</p>
<p><a name="p1556522"></a>30 mg:  dark blue, film-coated, round, biconvex,
bevel-edged tablets debossed with â€œT30â€? on one side and the Boehringer
Ingelheim company symbol on the other side.<br>Unit of use
bottles of 30â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†NDC:  0597-0137-30</p>
<p><a name="p1554322"></a>20 mg:  white to slightly yellowish, film-coated, round,
biconvex, bevel-edged tablets debossed with â€œT20â€? on one side and
the Boehringer Ingelheim company symbol on the other side.<br>Unit of use bottles of 30â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†â€†NDC:  0597-0141-30</p>
<p><a name="p10527222"></a><span class="Italics">Storage</span><br>Store
at 25Â°C (77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F) [see USP
Controlled Room Temperature].  Dispense medication in the original
container to protect from exposure to high humidity and light.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="P35"></a><span class="Italics">See FDA-approved patient labeling (Patient Information)</span></p>
<br><ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span><br>Advise patients that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
occurs in nearly all patients who receive GILOTRIF. Inform patients
that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may result in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> if not
treated. Advise patients to notify their physician if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> develops
and to seek medical attention promptly for severe or persistent <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>) and Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span>
</li>
<li>
<span class="Bold">Bullous and Exfoliative <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Disorders</span></span><br>Advise patients to minimize sun exposure with protective clothing
and use of sunscreen while taking GILOTRIF <span class="Italics">[see Warnings and
Precautions (<a href="#Section_5.2">5.2</a>)].</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></span><br>Advise
patients to immediately report any new or worsening lung symptoms,
or any combination of the following symptoms: trouble breathing or
<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.3">5.3</a>)].</span>
</li>
<li>
<span class="Bold">Hepatic Toxicity</span><br>Advise patients
that they will need to undergo liver function monitoring periodically.
Advise patients to immediately report any symptoms of a liver problem
(e.g., skin or the whites of eyes turn yellow, urine turns dark or
brown (tea colored), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of stomach, bleed or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span>
more easily than normal, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>) <span class="Italics">[see Warnings and Precautions
(<a href="#Section_5.4">5.4</a>)].</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span></span><br>Advise patients to immediately
report eye problems (e.g., <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>,
or other vision changes) <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].</span>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span><br>Advise
patients to contact a healthcare professional immediately for any
of the following:  new onset or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or exercise
intolerance, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the ankles/legs, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>,
or sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> <span class="Italics">[see Dosage and Administration (<a href="#Section_2.3">2.3</a>) and Adverse Reactions (<a href="#Section_6.1">6.1</a>)].</span>
</li>
<li>
<span class="Bold">Instructions for Taking GILOTRIF</span><br>Advise patients to take GILOTRIF on an empty stomach at least 1
hour before or 2 hours after eating <span class="Italics">[see Dosage and Administration
(<a href="#Section_2.2">2.2</a>)]. </span>Advise patients not
to take a missed dose within 12 hours of the next dose.</li>
<li>
<span class="Bold">Embryofetal Toxicity</span><br>Counsel patients
on pregnancy planning and prevention. Advise females of reproductive
potential to use highly effective contraception during treatment,
and for at least 2 weeks after taking the last dose of GILOTRIF <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.6">5.6</a>) and Use in Specific Populations (<a href="#Section_8.1">8.1</a>)].</span>
</li>
<li>
<span class="Bold">Nursing Mothers</span><br>Advise patients
to discontinue nursing while taking GILOTRIF <span class="Italics">[see Use in Specific
Populations (<a href="#Section_8.3">8.3</a>)].</span>
</li>
</ul>
<p><a name="p11788122"></a>Distributed by:<br>Boehringer
Ingelheim Pharmaceuticals, Inc.<br>Ridgefield, CT 06877 USA</p>
<p><a name="p11791322"></a>Licensed from:<br>Boehringer Ingelheim
International GmbH</p>
<p><a name="p11796322"></a>GILOTRIF is
a registered trademark of and used under license from Boehringer Ingelheim
International GmbH.</p>
<p><a name="p11797222"></a>The other
brands listed are trademarks of their respective owners and are not
trademarks of Boehringer Ingelheim Pharmaceuticals, Inc.</p>
<p><a name="p11800222"></a>Copyright Â© 2015 Boehringer Ingelheim International
GmbH<br>ALL RIGHTS RESERVED</p>
<p><a name="p11807522"></a>IT5562JG022015<br>302972-06</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s1794422"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><a name="p1584322"></a><span class="Bold">Patient Information</span></p>
<p><a name="p1583422"></a><span class="Bold">GILOTRIF<span class="Sup">Â®</span> (JEE-loh-trif)<br>(afatinib)<br>tablets</span></p>
<p><a name="p11814122"></a>Read this Patient Information before you
start taking GILOTRIF and each time you get a refill. There may be
new information. This information does not take the place of talking
to your doctor about your medical condition or treatment.</p>
<p><a name="p11815222"></a><span class="Bold">What is GILOTRIF?</span></p>
<p><a name="p11822122"></a>â€†â€†â€†â€†â€†GILOTRIF is a prescription medicine
used to treat people with non-small cell lung cancer (NSCLC),</p>
<ul class="Disc">
<li>that has certain types of abnormal epidermal growth factor
receptor (EGFR) genes, and</li>
<li>who have not had previous treatment for cancer that has
spread to other parts of the body<br>It is not known if GILOTRIF
is safe and effective in children.</li>
</ul>
<p><a name="p12080222"></a><span class="Bold">What should I tell my doctor
before taking GILOTRIF?</span></p>
<p class="ListCaption">â€‡Before you take GILOTRIF, tell your doctor if you:</p>
<ul class="Disc">
<li>have kidney or liver problems</li>
<li>have lung or breathing problems other than lung cancer</li>
<li>have a history of severe <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span> or any other eye problems.
Tell your doctor if you wear contact lenses.</li>
<li>have heart problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. GILOTRIF can harm
your unborn baby.  You should not become pregnant while taking GILOTRIF.<ul class="Disc">
<li>Women who are able to become pregnant should use effective
birth control during treatment with GILOTRIF and for at least 2 weeks
after your last dose of GILOTRIF. Talk to your doctor about birth
control methods that may be right for you.</li>
<li>Tell your doctor right away if you become pregnant while
taking GILOTRIF.</li>
</ul>
</li>
<li>are breastfeeding or plan to breastfeed. It is not known
if GILOTRIF passes into your breast milk. You and your doctor should
decide if you will take GILOTRIF or breastfeed. You should not do
both.<br><br><span class="Bold">Tell your doctor about all the
medicines you take, </span>including prescription and over-the-counter
medicines, vitamins, and herbal supplements. GILOTRIF may affect the
way other medicines work, and other medicines may affect the way GILOTRIF
works.<br><br>Know the medicines you take. Keep a
list of them to show your doctor or pharmacist when you get a new
medicine.</li>
</ul>
<p class="ListCaption">How should I take GILOTRIF?</p>
<ul class="Disc">
<li>Take GILOTRIF exactly as your doctor tells you to take it.</li>
<li>Your doctor will tell you how many GILOTRIF tablets to take
and when to take them. Do not change your dose or stop GILOTRIF unless
your doctor tells you to.</li>
<li>Take GILOTRIF on an empty stomach at least 1 hour before
a meal or 2 hours after a meal.</li>
<li>If you miss a dose of GILOTRIF, take it as soon as you remember.
If it is within 12 hours of your next dose, skip the dose and just
take your next dose at your regular time.</li>
<li>Do not take 2 doses of GILOTRIF at the same time.</li>
<li>If you take too much GILOTRIF, call your doctor or go to
the nearest hospital emergency room right away.</li>
</ul>
<p><a name="p13352722"></a><span class="Bold">What should I avoid while taking
GILOTRIF?</span></p>
<p><a name="p13568122"></a>Limit your time
in the sun. GILOTRIF can make your skin sensitive to the sun. You
could get or have worsening <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. You could get a severe sunburn.
Use sunscreen and wear a hat and clothes that cover your skin while
you are taking GILOTRIF if you have to be in sunlight.</p>
<p><a name="p13569222"></a><span class="Bold">What are the possible side effects
of GILOTRIF?</span></p>
<p><a name="p16424322"></a>â€†â€†â€†â€†â€†â€†â€†â€†
                     <span class="Bold">GILOTRIF may cause serious side effects, </span>including:</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is common with GILOTRIF
and may sometimes be severe. Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can cause loss of body
fluid (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>) and kidney problems that can sometimes lead to
<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. During your treatment with GILOTRIF, your doctor should prescribe
medicines to treat <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Take this medicine exactly as your doctor
tells you to. Tell your doctor if you have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Get medical attention
right away if your <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> does not go away or becomes severe.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> GILOTRIF can cause <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>,
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. It is important to get treatment for <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>
as soon as you notice them. Take medicines to help <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>
exactly as your doctor tells you to. Get medical attention right away
if you develop severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>
of the skin.</li>
<li>
<span class="Bold">lung or breathing problems.</span> Tell your doctor
right away if you have any new or worsening lung problems, or any
combination of the following symptoms:<ul class="Disc">
<li>trouble breathing or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
</ul>
</li>
<li>
<span class="Bold">liver problems.</span> Tell your doctor right away
if you have any symptoms of a liver problem which may include:<ul class="Disc">
<li>yellowing of your skin or the white part of your eyes (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>dark or brown (tea colored) urine</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the upper right side of your stomach area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> more easily than normal</li>
<li>feeling very tired</li>
</ul>
</li>
</ul>
<p><a name="p14598722"></a>â€†â€†â€†Your doctor will do blood tests
to check your liver function during your treatment with GILOTRIF.</p>
<ul class="Disc">
<li>
<span class="Bold">eye problems.</span> Tell your doctor right away if
you have symptoms of eye problems which may include:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or tearing</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></li>
<li>sensitivity to light</li>
<li>other changes in your vision</li>
</ul>
</li>
<li>
<span class="Bold">heart problems.</span> Tell your doctor right away
if you have symptoms of a heart problem which may include:<ul class="Disc">
<li>new or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> while at rest or with
activity</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles, feet, or legs</li>
<li>feeling that your heart is pounding or racing (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>)</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
</ul>
</li>
</ul>
<p class="ListCaption">The most common side effects of GILOTRIF include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>mouth sores</li>
<li><span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span><br><br>Tell your doctor if you have
any side effect that bothers you or that does not go away.<br><br>These are not all of the possible side effects of GILOTRIF.
For more information, ask your doctor or pharmacist.<br><br>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</li>
</ul>
<p class="ListCaption">How should I store GILOTRIF?</p>
<ul class="Disc">
<li>Store GILOTRIF at room temperature between 68Â°F to 77Â°F
(20Â°C to 25Â°C).</li>
<li>Keep GILOTRIF in the original container and keep the container
tightly closed.</li>
<li>Keep GILOTRIF away from moisture and light.</li>
<li>Safely throw away (discard) any GILOTRIF that is out of
date or no longer needed.</li>
</ul>
<p><a name="p16424522"></a><span class="Bold">Keep GILOTRIF and all medicines
out of the reach of children.</span></p>
<p><a name="p16426322"></a><span class="Bold">General information about GILOTRIF</span></p>
<br><dl class="None">
<dt></dt>
<dd>Medicines are sometimes prescribed for
purposes other than those listed in a Patient Information leaflet.
Do not use GILOTRIF for a condition for which it was not prescribed.
Do not give GILOTRIF to other people, even if they have the same symptoms
you have. It may harm them.</dd>
</dl>
<br><dl class="None">
<dt></dt>
<dd>This Patient Information summarizes the
most important information about GILOTRIF. If you would like more
information about GILOTRIF, talk with your doctor. You can ask your
doctor or pharmacist for information about GILOTRIF that is written
for health professionals.</dd>
</dl>
<br><dl class="None">
<dt></dt>
<dd>For more information, go to <span class="Underline">www.gilotrif.com</span> or call Boehringer Ingelheim Pharmaceuticals,
Inc. at 1-800-542-6257 or (TTY) 1-800-459-9906, or scan the code below
to go to <span class="Underline">www.gilotrif.com</span>.</dd>
</dl>
<div class="Figure"><img alt="Gilotrif Barcode" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=gilotrif-barcode.jpg"></div>
<p><a name="p16671122"></a><span class="Bold">What are the ingredients in GILOTRIF?</span></p>
<br><dl class="None">
<dt></dt>
<dd>
<span class="Bold">Active ingredient:</span> afatinib<br><br><span class="Bold">Inactive ingredients:</span> Tablet Core: lactose
monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon
dioxide, magnesium stearate.<br>Tablet Coating: hypromellose,
polyethylene glycol, titanium dioxide, talc, polysorbate 80, FD&amp;C
Blue No. 2 (40 mg and 30 mg tablets only).</dd>
</dl>
<p><a name="p16898622"></a><span class="Bold">This Patient Information has
been approved by the U.S. Food and Drug Administration.</span></p>
<br><br><p><a name="p16907322"></a>Distributed by:<br>Boehringer Ingelheim Pharmaceuticals, Inc.<br>Ridgefield,
CT 06877 USA</p>
<p><a name="p16914522"></a>Licensed from:<br>Boehringer Ingelheim International GmbH</p>
<p><a name="p16919522"></a>GILOTRIF is a registered trademark of and used under
license from Boehringer Ingelheim International GmbH.</p>
<p><a name="p16920422"></a>Copyright Â© 2015 Boehringer Ingelheim International
GmbH<br>ALL RIGHTS RESERVED</p>
<p><a name="p16927522"></a>Revised: August 2015</p>
<p><a name="p16928422"></a>IT5562JG022015<br>302972-06</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="gaffba1a1-24c2-d7e6-250e-bfc17211f0f2"></a><a name="section-17"></a><p></p>
<p class="First"><a name="p33221111"></a>Gilotrif<span class="Sup">Â®</span> 20 mg Tablets<br>NDC: 0597-0141-30</p>
<div class="Figure"><img alt="20 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=20-mg-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g3cde0e82-c4f9-7570-fbcb-083df902e0d8"></a><a name="section-18"></a><p></p>
<p class="First"><a name="p3322222223523"></a>Gilotrif<span class="Sup">Â®</span> 30 mg Tablets<br>NDC: 0597-0137-30</p>
<div class="Figure"><img alt="30 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=30-mg-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="gb4694ddb-edd1-0650-1c28-4853850191e0"></a><a name="section-19"></a><p></p>
<p class="First"><a name="p33223333"></a>Gilotrif<span class="Sup">Â®</span> 40 mg Tablets<br>NDC: 0597-0138-30</p>
<div class="Figure"><img alt="40 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd638e5e-8032-e7ca-0179-95e96ab5d387&amp;name=40-mg-carton.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GILOTRIFÂ 		
					</strong><br><span class="contentTableReg">afatinib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0141</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>afatinib</strong> (afatinib) </td>
<td class="formItem">afatinib</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (Slightly yellowish) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0141-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201292</td>
<td class="formItem">07/12/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GILOTRIFÂ 		
					</strong><br><span class="contentTableReg">afatinib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0137</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>afatinib</strong> (afatinib) </td>
<td class="formItem">afatinib</td>
<td class="formItem">30Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Dark Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0137-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201292</td>
<td class="formItem">07/12/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GILOTRIFÂ 		
					</strong><br><span class="contentTableReg">afatinib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0138</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>afatinib</strong> (afatinib) </td>
<td class="formItem">afatinib</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">T40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0138-30</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA201292</td>
<td class="formItem">07/12/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc.
							(603175944)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc. (603175944)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH &amp; Co. KG</td>
<td class="formItem"></td>
<td class="formItem">551147440</td>
<td class="formItem">MANUFACTURE(0597-0141, 0597-0137, 0597-0138), API MANUFACTURE(0597-0137, 0597-0138, 0597-0141), LABEL(0597-0137, 0597-0138, 0597-0141), ANALYSIS(0597-0141, 0597-0138, 0597-0137), PACK(0597-0138, 0597-0137, 0597-0141)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane, Inc.</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">LABEL(0597-0137, 0597-0138, 0597-0141), PACK(0597-0138, 0597-0137, 0597-0141)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4bdbf17b-b7b7-0145-cc59-8403ff1ba5fa</div>
<div>Set id: fd638e5e-8032-e7ca-0179-95e96ab5d387</div>
<div>Version: 6</div>
<div>Effective Time: 20150801</div>
</div>
</div>Â <div class="DistributorName">Boehringer Ingelheim Pharmaceuticals, Inc.</div></p>
</body></html>
